# Astellas Pharma China, Inc. clinical trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Astellas Pharma China, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Astellas Pharma China, Inc.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/astellas-pharma-china-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 10, 2021 | NCT05153915 | A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney... | Astellas Pharma China, Inc. | Phase 4 | Completed | Liver Transplantation, Kidney Transplantation | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05153915) |
| December 10, 2021 | NCT05152628 | A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric... | Astellas Pharma China, Inc. | Phase 4 | Completed | Liver Transplantation, Kidney Transplantation | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05152628) |
| August 9, 2021 | NCT04995419 | A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who... | Astellas Pharma China, Inc. | Phase 2 | Completed | Metastatic Urothelial Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04995419) |
| March 11, 2021 | NCT04793204 | A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects | Astellas Pharma China, Inc. | Phase 1 | Completed | Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04793204) |
| September 24, 2020 | NCT04562090 | A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder | Astellas Pharma China, Inc. | Phase 4 | Completed | Urge Incontinence, Overactive Bladder (OAB) | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04562090) |
| August 6, 2020 | NCT04501640 | A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants | Astellas Pharma China, Inc. | Phase 4 | Completed | Pharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04501640) |
| June 30, 2020 | NCT04451226 | A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated... | Astellas Pharma China, Inc. | Phase 3 | Completed | Hot Flashes | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04451226) |
| January 21, 2020 | NCT04234204 | A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause | Astellas Pharma China, Inc. | Phase 3 | Completed | Hot Flashes | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04234204) |
| October 29, 2019 | NCT04143477 | A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects | Astellas Pharma China, Inc. | Phase 1 | Completed | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04143477) |
| September 12, 2019 | NCT04086758 | A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or... | Astellas Pharma China, Inc. | Phase 1 | Completed | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04086758) |
| September 6, 2018 | NCT03660059 | A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or... | Astellas Pharma China, Inc. | Phase 3 | Completed | Rheumatoid Arthritis (RA) | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03660059) |
| August 23, 2018 | NCT03644485 | Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After... | Astellas Pharma China, Inc. | Phase 4 | Completed | Kidney Transplant | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03644485) |
| March 11, 2016 | NCT02706678 | Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients | Astellas Pharma China, Inc. | Phase 4 | Completed | Renal Transplant Recipients | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02706678) |
| February 10, 2016 | NCT02678598 | A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections | Astellas Pharma China, Inc. | Observational | Completed | Invasive Fungal Infections | 2,555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02678598) |
| January 6, 2016 | NCT02646800 | Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp | Astellas Pharma China, Inc. | Phase 4 | Terminated | Aspergillosis, Candidiasis | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02646800) |
| January 6, 2016 | NCT02646774 | Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis | Astellas Pharma China, Inc. | Phase 4 | Terminated | Invasive Aspergillosis | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02646774) |
| May 29, 2015 | NCT02457221 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis | Astellas Pharma China, Inc. | Phase 3 | Completed | Lupus Nephritis | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02457221) |
| March 18, 2015 | NCT02392312 | Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients | Astellas Pharma China, Inc. | Observational | Completed | Kidney Transplant Recipients | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02392312) |
| October 20, 2014 | NCT02268201 | A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release... | Astellas Pharma China, Inc. | Phase 4 | Terminated | Kidney Transplant Recipients | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268201) |
| May 15, 2014 | NCT02138773 | A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted... | Astellas Pharma China, Inc. | Phase 1 | Completed | Healthy, Pharmacokinetics of Tamsulosin Hydrochloride | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02138773) |
| November 13, 2013 | NCT01982071 | A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia | Astellas Pharma China, Inc. | Phase 4 | Terminated | Candidemia, Candidiasis | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01982071) |
| June 7, 2013 | NCT01872039 | Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients | Astellas Pharma China, Inc. | Phase 4 | Completed | Hypertension Emergency, End-organ Damage | 163 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01872039) |
| December 10, 2012 | NCT01745159 | Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis | Astellas Pharma China, Inc. | Phase 4 | Completed | Moderate/Severe Atopic Dermatitis | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01745159) |
| November 2, 2012 | NCT01720212 | Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers | Astellas Pharma China, Inc. | Phase 1 | Completed | Healthy Chinese Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01720212) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Phase 4 | 12 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Aspergillosis | 3 |
| Candidiasis | 2 |
| Hot Flashes | 2 |
| Urinary Incontinence, Urge | 1 |
| Urinary Bladder, Overactive | 1 |
| Candidemia | 1 |
| Invasive Fungal Infections | 1 |
| Torulopsis | 1 |
| Lupus Nephritis | 1 |
| Adenocarcinoma | 1 |
| Lymphoma, Follicular | 1 |
| Dermatitis, Atopic | 1 |
| Hypertension | 1 |
| Arthritis, Rheumatoid | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
- [Drama schools in the United States](https://specstream.ai/data/businesses/drama-schools/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Generator installation repair companies in the United States](https://specstream.ai/data/businesses/generator-installation-repair-companies/united-states)
